Search

Your search keyword '"Di Bisceglie, Adrian M"' showing total 79 results
Start Over Author "Di Bisceglie, Adrian M" Publisher lippincott williams & wilkins
79 results on '"Di Bisceglie, Adrian M"'

2. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.

Author

Terrault, Norah A., Lok, Anna S., Wahed, Abdus S., Ghany, Marc G., Perrillo, Robert P., Fried, Michael W., Wong, David K., Khalili, Mandana, Lau, Daryl T. Y., Sterling, Richard K., Di Bisceglie, Adrian M., Lisker-Melman, Mauricio, Cooper, Stewart L., Chung, Ray T., Patel, Keyur, Roberts, Lewis R., Belle, Steven H., and Janssen, Harry L. A.

Published
2023
Full Text
View/download PDF

4. Changes in serum hepatitis B surface and e antigen, interferon‐inducible protein 10, and aminotransferase levels during combination therapy of immune‐tolerant chronic hepatitis B.

Author

Perrillo, Robert, Lin, Hsing‐Hua S., Schwarz, Kathleen B., Rosenthal, Philip, Lisker‐Melman, Mauricio, Chung, Raymond T., Prokunina‐Olsson, Ludmila, Coherty, Gavin, Feld, Jordan, Lau, Daryl T‐Y, Roberts, Lewis R., Hassan, Mohamed A., Schwarzenberg, Sarah Jane, Di Bisceglie, Adrian M., Teckman, Jeffrey, Janssen, Harry L. A., Wong, David K., Juan, Joshua, Yim, Colina, and Patel, Keyur

Published
2022
Full Text
View/download PDF

5. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.

Author

Lok, Anna S., Perrillo, Robert, Lalama, Christina M., Fried, Michael W., Belle, Steven H., Ghany, Marc G., Khalili, Mandana, Fontana, Robert J., Sterling, Richard K., Terrault, Norah, Feld, Jordan J., Di Bisceglie, Adrian M., Lau, Daryl T.Y., Hassan, Mohamed, Janssen, Harry L.A., Chung, Raymond T, Roberts, Lewis R, Lisker‐Melman, Mauricio, Wong, David K, and Juan, Joshua

Published
2021
Full Text
View/download PDF

6. A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC.

Author

Cabrera, Roniel, Singal, Amit G., Colombo, Massimo, Kelley, R. Kate, Lee, Hannah, Mospan, Andrea R., Meyer, Tim, Newell, Pippa, Parikh, Neehar D., Sangro, Bruno, Reddy, K. Rajender, Watkins, Stephanie, Zink, Richard C., and Di Bisceglie, Adrian M.

Subjects
HEPATOCELLULAR carcinoma, CLINICS, RADIOLOGY, HEPATITIS C virus, LIVER diseases
Abstract

This study describes the design of the TARGET‐hepatocellular carcinoma (HCC) cohort and descriptive characteristics of the patient population at diagnosis among those who were enrolled in the cohort across academic and community clinical centers. TARGET‐HCC is a 5‐year, longitudinal, observational cohort of patients with HCC receiving care in usual clinical practice. Redacted clinical information, obtained from medical records, captures the natural history and management of the disease, including the safety and efficacy of treatment interventions used in usual clinical practice. Patients can complete patient‐reported outcome measures and provide biological specimens for future translational studies. The TARGET‐HCC study includes adults with histologic, cytologic, or radiologic diagnosis of HCC from academic and community centers in both the United States and Europe. A total of 1,841 participants were enrolled between January 9, 2017, and July 23, 2019, at 67 sites in the United States and Europe. To date, the most common liver disease etiology in the cohort continues to be hepatitis C, although nearly half had a nonviral etiology, including alcohol‐related liver disease or nonalcoholic steatohepatitis. Most included patients were diagnosed at an early stage (Barcelona Clinic Liver Cancer Stage [BCLC] 0/A), but only approximately one third underwent curative treatment. Systemic therapy has been used in 7.3% of enrolled patients, including 45.7% of those with BCLC stage C tumors. Conclusion: Overall, the TARGET‐HCC cohort allows for the assessment of patient characteristics and investigation of new treatment paradigms and sequencing with existing agents as well as novel regimens for HCC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

7. Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis.

Author

Radhakrishnan, Kavita, Di Bisceglie, Adrian M., Reddy, K. Rajender, Lim, Joseph K., Levitsky, Josh, Hassan, Mohamed A., Darling, Jama M., Feld, Jordan J., Akushevich, Lucy, Vainorius, Monika, Nelson, David R., Fried, Michael W., Brown, Robert S., and Terrault, Norah A.

Subjects
LIVER cancer, PATIENTS, GENOTYPES
Abstract

Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs). We compared the effectiveness of DAAs in patients with cirrhosis, with and without HCC, and in those with HCC partially treated or untreated (PT/UT‐HCC) versus completely treated (CT‐HCC). HCC status was based on imaging 6 months before or 2 months after start of DAA therapy. Absence and presence of enhancing lesions after HCC treatment defined CT‐HCC and PT/UT‐HCC, respectively. Using minimally adjusted logistic regression, the association between the presence of HCC and SVR rates was estimated. Among the 1,457 patients with cirrhosis from HCV‐TARGET with complete virologic data (per‐protocol population) who did not undergo liver transplantation during treatment and followup, 1,300 were without HCC, 91 with CT‐HCC, and 66 with PT/UT‐HCC. Most patients were genotype 1 (81%) and treatment‐experienced (56%), 41% had history of prior decompensation, and the median pretreatment Model for End‐Stage Liver Disease was 9 (range 6‐39). The SVR rates were 91% for patients without HCC, 84% for CT‐HCC, and 80% for PT/UT‐HCC. The presence of HCC (versus not having HCC) was associated with significantly lower odds of achieving SVR (odds ratio [OR] = 0.51, 95% confidence interval [CI]: 0.33‐0.81; P = 0.003). However, among those with HCC, HCC treatment status (PT/UT‐HCC versus CT‐HCC) did not show association with SVR (OR = 0.79, 95% CI: 0.35‐1.79, P = 0.569). Conclusions: The presence of HCC reduces the likelihood of SVR by 50%, but with no evident difference in those with completely treated HCC versus partially treated/untreated HCC. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

10. Diabetes and prediabetes in patients with hepatitis B residing in North America.

Author

Khalili, Mandana, Lombardero, Manuel, Chung, Raymond T., Terrault, Norah A., Ghany, Marc G., Kim, W. Ray, Lau, Daryl, Lisker‐Melman, Mauricio, Sanyal, Arun, Lok, Anna S., Roberts, Lewis R., Smith, Coleman I., Di Bisceglie, Adrian M., Brunt, Elizabeth M., Janssen, Harry L.A., Wong, David K., Juan, Joshua, Feld, Jordan, Yim, Colina, and Heathcote, Jenny

Published
2015
Full Text
View/download PDF

12. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.

Author

Marcellin, Patrick, Craxi, Antonio, Brandao-Mello, Carlos E, Di Bisceglie, Adrian M, Andreone, Pietro, Freilich, Bradley, Rajender Reddy, K, Olveira Martín, Antonio, Teuber, Gerlinde, Messinger, Diethelm, Hooper, Greg, Wat, Cynthia, Tatsch, Fernando, and Jensen, Donald M

Published
2013
Full Text
View/download PDF

20. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Author

Welzel, Tania Mara, Morgan, Timothy R., Bonkovsky, Herbert L., Naishadham, Deepa, Pfeiffer, Ruth M., Wright, Elizabeth C., Hutchinson, Amy A., Crenshaw, Andrew T., Bashirova, Arman, Carrington, Mary, Dotrang, Myhanh, Sterling, Richard K., Lindsay, Karen L., Fontana, Robert J., Lee, William M., Di Bisceglie, Adrian M., Ghany, Marc G., Gretch, David R., Chanock, Stephen J., and Chung, Raymond T.

Published
2009
Full Text
View/download PDF

31. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.

Author

Combes, Burton, Emerson, Scott S., Flye, Nancy L., Munoz, Santiago J., Luketic, Velimir A., Mayo, Marlyn J., McCashland, Timothy M., Zetterman, Rowen K., Peters, Marion G., Di Bisceglie, Adrian M., Benner, Kent G., Kowdley, Kris V., Carithers, Robert L., Rosoff, Leonard, Garcia-Tsao, Guadalupe, Boyer, James L., Boyer, Thomas D., Martinez, Enrique J., Bass, Nathan M., and Lake, John R.

Published
2005
Full Text
View/download PDF

41. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial.

Author

Di Bisceglie, Adrian M., Bonkovsky, Herbert L., Chopra, Sanjiv, Flamm, Stephen, Reddy, Rajender K., Grace, Norman, Killenberg, Paul, Hunt, Christine, Tamburro, Carlo, Tavill, Anthony S., Ferguson, Roy, Krawitt, Edward, Banner, Barbara, and Bacon, Bruce R.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results